Tilray Brands, Inc. (TLRY.TO)

Negative net income growth while Drug Manufacturers - Specialty & Generic median is 13.99%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.

D&A growth of 58.54% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.

Deferred tax shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.

SBC growth of 116.21% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.

Working capital is shrinking yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage if sales remain robust.

AR shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see an advantage in working capital if sales do not drop.

Inventory growth of 124.76% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question if expansions or new product lines require extra stock.

AP shrinks yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.

Growth of 70.64% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.

Other non-cash items dropping yoy while Drug Manufacturers - Specialty & Generic median is -41.16%. Seth Klarman would see a short-term advantage if real fundamentals remain intact.

Negative CFO growth while Drug Manufacturers - Specialty & Generic median is -11.62%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.

CapEx declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.

Acquisition spending declines yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would note reduced M&A risk if growth continues organically.

Investment purchases shrink yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a short-term cash advantage if no high-return opportunities are missed.

We liquidate less yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see a firm-specific hold strategy unless missed gains exist.

Growth of 336.42% while Drug Manufacturers - Specialty & Generic median is zero at 0.00%. Walter Schloss questions intangible or special projects explaining that difference.

Reduced investing yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.

We reduce issuance yoy while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.

No Data available this quarter, please select a different quarter.